Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer

HER family members are interdependent and functionally compensatory. Simultaneously targeting EGFR/HER2/HER3 by antibody combinations has demonstrated superior treatment efficacy over targeting one HER receptor. However, antibody combinations have their limitations, with high immunogenicity and high...

Full description

Bibliographic Details
Main Authors: Xiaolin Yu, Sharad Ghamande, Haitao Liu, Lu Xue, Shuhua Zhao, Wenxi Tan, Lijing Zhao, Shou-Ching Tang, Daqing Wu, Hasan Korkaya, Nita J. Maihle, Hong Yan Liu
Format: Article
Language:English
Published: Elsevier 2018-03-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
aptamer
siRNA
HER family
HER2
HER3
EGFR
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253117303165

Similar Items

Similar Items